Detecting Drug Resistance in Leukaemia with 99Tcm-MIBI
Author Information
Author(s): A Gruber, I Arestrom, D Xu, J Liliemark, SA Larsson, H Jacobsson
Primary Institution: Karolinska Hospital
Hypothesis
Can 99Tcm-MIBI be used as a marker for mdrl gene expression in leukaemic cells and can cyclosporin A modify its accumulation?
Conclusion
99Tcm-MIBI can effectively detect low levels of mdrl gene expression in leukaemic cells and its accumulation can be significantly increased by cyclosporin A.
Supporting Evidence
- 99Tcm-MIBI accumulation was significantly higher in mdrl-negative cells compared to mdrl-positive cells.
- CyA increased 99Tcm-MIBI accumulation by 30% in mdrl-negative cells and 242% in mdrl-positive cells.
- The study confirms the high sensitivity of 99Tcm-MIBI for detecting P-glycoprotein expression.
Takeaway
This study shows that a special substance called 99Tcm-MIBI can help doctors see if leukaemia cells are resistant to treatment, and a medicine called cyclosporin A can help it work better.
Methodology
Leukaemic cells from ten patients were incubated with 99Tcm-MIBI and daunorubicin, with and without cyclosporin A, to measure drug accumulation.
Limitations
The study had a small sample size and results may not be generalizable to all leukaemia patients.
Participant Demographics
Patients with acute myelocytic leukaemia, five with undetectable mdrl gene expression and five with varying levels of mdrl mRNA.
Statistical Information
P-Value
0.009
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website